Reviva Pharmaceutcls Hldgs Inc Stock Price, News & Analysis

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a $10 million public offering. The offering includes 20 million shares of common stock (or equivalents) at $0.50 per share, along with Series C and D warrants to purchase up to 20 million additional shares each.

The Series C warrants have a 5-year expiration while Series D warrants expire in 12 months, both with an exercise price of $0.50 per share. The offering is expected to close around June 27, 2025. Proceeds will fund R&D activities and general corporate purposes, with A.G.P./Alliance Global Partners acting as sole placement agent.

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will be managed by A.G.P./Alliance Global Partners as the sole placement agent.

The company plans to use the proceeds to fund research and development activities and for working capital purposes. The securities will be offered under an effective shelf registration statement filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for CNS, inflammatory and cardiometabolic diseases, announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update through a pre-recorded presentation, which will be available on-demand to registered conference attendees starting Monday, June 16, 2025, at 7:00 a.m. ET. The conference is scheduled for June 16-17, 2025, and will be held in a virtual format.

Reviva Pharmaceuticals (NASDAQ: RVPH) announced positive one-year data from its Phase 3 RECOVER open-label extension study of brilaroxazine for schizophrenia treatment. The study demonstrated sustained broad-spectrum efficacy across all symptom domains with a 35% discontinuation rate. The drug showed significant improvements in PANSS scores, with total score improvements of -10.7 at 6 months and -18.1 at 12 months. Safety data revealed only 8.5% of participants reported treatment-emergent adverse events, mostly mild (6.5%) or moderate (2.0%). Notable findings include minimal weight gain (1.52 kg), no drug-related serious adverse events, and improvements in multiple neuroinflammatory markers. The study's success supports brilaroxazine's potential as a novel treatment for schizophrenia, particularly addressing persistent negative symptoms and poor functional outcomes.

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for CNS, inflammatory and cardiometabolic diseases, has announced its participation in two upcoming investor conferences in May 2025.

CEO Laxminarayan Bhat will attend the Benchmark Healthcare House Call Virtual Investor Conference for a fireside chat and 1x1 meetings on May 29 at 11:15 a.m. ET, and the Lytham Partners Spring 2025 Investor Conference for a company presentation and 1x1 meetings on the same day at 2:00 p.m. ET. Both events will be held virtually.

Reviva Pharmaceuticals (NASDAQ: RVPH) reported Q1 2025 financial results and provided updates on its lead drug candidate brilaroxazine. The company completed its long-term open-label extension (OLE) trial with 446 participants, including 156 patients completing one year and 301 completing six months of treatment. The full dataset, including clinical response, safety, and biomarker data, is expected in Q2 2025. Reviva plans to initiate the Phase 3 RECOVER-2 trial in mid-2025 and targets an NDA submission in Q4 2026. Financially, Reviva reported a net loss of $6.4 million ($0.13 per share) for Q1 2025, compared to $7.4 million in Q1 2024. Cash position stood at $5.3 million as of March 31, 2025, down from $13.5 million at the end of 2024.

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming A.G.P. Healthcare Company Showcase. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat during the virtual event scheduled for May 21, 2025, at 2:00 p.m. EST.

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update through a fireside chat format.

The presentation is scheduled for Thursday, May 8, 2025, at 10:30 a.m. ET. Reviva focuses on developing therapies for:

• Central nervous system (CNS) diseases
• Inflammatory conditions
• Cardiometabolic diseases

The company aims to address unmet medical needs in these therapeutic areas. A webcast link has been provided for interested parties to access the presentation.

Reviva Pharmaceuticals (NASDAQ: RVPH) has announced an upcoming late-breaking poster presentation at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting. The presentation will focus on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia treatment.

The presentation, scheduled for May 28, 2025, from 11:15 a.m. to 1 p.m. MT at the Fairmont Scottsdale Princess in Arizona, will be delivered by Dr. Laxminarayan Bhat, the company's Founder, President, and CEO. The poster will detail brilaroxazine's effects on efficacy, safety, adherence, and biomarkers in patients with stable schizophrenia during the Phase 3 RECOVER trial extension.

Reviva, a late-stage pharmaceutical company, is developing therapies targeting unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases.